Goldman Sachs Asset Management led a $90m series A funding round in Nested Therapeutics.

Goldman Sachs Asset Management, an asset manager, led a $90m series A funding round in Nested Therapeutics, a biotech company. "Our drug discovery platform enables us to find new, overlooked areas of opportunity in the form of high confidence targets with unconventional pockets, while also generating the insights necessary to design therapeutics with novel mechanisms for a perfect fit. Patients deserve more and better options, and our approach holds the promise to make first- and best-in-class precision oncology treatments available to a larger addressable population," Darrin Miles, Nested Therapeutics CEO.